Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 19;30(2):1416-1425.
doi: 10.3390/curroncol30020108.

Management of Oligometastatic Breast Cancer: An Expert Committee's Opinion

Dominique Leblanc  1 , Guy Cantin  1 , Alexandra Desnoyers  1 , Jean Dufresne  2 , Giuseppina Laura Masucci  3 , Valérie Panet-Raymond  4 , Éric Poirier  1 , Sara Soldera  5 , Isabelle Gingras  6
Affiliations

Management of Oligometastatic Breast Cancer: An Expert Committee's Opinion

Dominique Leblanc et al. Curr Oncol. .

Abstract

Patients with oligometastatic breast cancer (BC) are candidates of choice for metastasis-directed therapy (MDT). This paper summarizes the opinions of an expert committee about the management of oligometastatic BC. The experts could complete the questionnaire from 13 September 2021, to 10 October 2021, followed by a discussion. The experts were physicians working in the Province of Quebec (Canada) and specialized in BC care, including surgical oncologists, medical oncologists, and radiation oncologists. The experts provided their opinions about the context of the disease and therapeutic approach, local and systemic therapies, and the prognosis of oligometastatic BC. In addition to the expert panel's opinions about the management of oligometastatic disease per se, the experts stated that a prospective data registry should be implemented to collect data about oligometastatic BC to improve knowledge about oligometastatic BC and implement data-driven MDT. These data could also allow for the design of treatment algorithms. In conclusion, this paper presents the expert panel's opinions about the management of oligometastatic BC and highlights the needs to be met to improve the care of this condition.

Keywords: breast cancer; expert opinion; management; metastasis.

PubMed Disclaimer

Conflict of interest statement

Expert committees for Pfizer, Novartis, and AstraZeneca, D.L.; none, G.C.; conferences for AstraZeneca, Apobiologix, Eli Lilly, Novartis, Pfizer, and Seagen; expert committees for Gilead, LaRoche-Posay, Eli Lilly, Novartis, Pfizer, and Seagen, A.D.; none J.D., G.L.M., V.P.R., E.V. and S.S.; expert committees for Pfizer, Eli Lilly, AstraZeneca, Merck, Gilead, and Novartis; honorarium from Eli Lilly, Pfizer, and Novartis, I.G. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

References

    1. Fisher B. Laboratory and clinical research in breast cancer—A personal adventure: The David A. Karnofsky memorial lecture. Cancer Res. 1980;40:3863–3874. - PubMed
    1. Lee R.M., Cardona K., Russell M.C. Historical perspective: Two decades of progress in treating metastatic colorectal cancer. J. Surg. Oncol. 2019;119:549–563. doi: 10.1002/jso.25431. - DOI - PubMed
    1. Park C.K., Kim D.G. Historical background. Prog Neurol Surg. 2012;25:1–12. - PubMed
    1. Hellman S. Karnofsky Memorial Lecture. Natural history of small breast cancers. J. Clin. Oncol. 1994;12:2229–2234. doi: 10.1200/JCO.1994.12.10.2229. - DOI - PubMed
    1. Hellman S., Weichselbaum R.R. Oligometastases. J. Clin. Oncol. 1995;13:8–10. doi: 10.1200/JCO.1995.13.1.8. - DOI - PubMed

Publication types